Safety and Efficacy of Stereotactic Ablative Radiotherapy Plus Durvalumab for Early-Stage Medically Inoperable NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
International Journal of Radiation Oncology, Biology, Physics
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer
Int. J. Radiat. Oncol. Biol. Phys 2023 Apr 05;[EPub Ahead of Print], TC Wu, A Stube, C Felix, D Oseguera, T Romero, J Goldman, EB Garon, JM Lee, J Glaspy, AE Lisberg, CG Rusthoven, DR Camidge, S Siva, B Solomon, A Lee, SE Tenn, N Shaverdian, ML Steinberg, AC Raldow, P LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.